Optimizing decisions on cancer treatment for patients with advanced lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the impact of an optimization device designed to assist oncologists and patients in making informed decisions about continuing or stopping cancer treatments for advanced Non-Small-Cell Lung Carcinoma (NSCLC). It involves a sequential comparative approach, where one group receives usual care while another group uses the optimization device to guide discussions about treatment options. The device incorporates clinical parameters, doctor and patient expectations, and the possibility of supportive care, aiming to enhance shared decision-making. The study will measure the rate of systemic oncological treatment during the last month of life across both groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically or cytologically proven non-small-cell lung carcinoma (NSCLC) including NSCLC with oncogene addiction.
2. Stage IV or IIB/IIIC non irradiable (8th classification TNM, UICC 2015)
3. Patient having completed at least one line of chemotherapy in the context of metastatic disease (or in the context of locoregional disease if the last chemotherapy was less than 6 months ago).
4. ECOG Performance Status ≥ 2.
5. Age ≥ 18.
6. Written informed consent.
7. Patient capable, according to the investigator, to comply with the requirements of the study.

Exclusion Criteria:

1. Small Cell Lung Cancer (including mixed forms).
2. Patient with NSCLC for whom a decision has already been made to permanently discontinue all systemic cancer treatment.
3. Impossible follow up for geographical, social or psychological reason.
4. Inability to answer a questionnaire (language or neurological barrier).
5. Patient under guardianship.
6. Patient being treated in a therapeutic trial.
7. Patient not covered by social security. -

Where it's running

• CH Abbeville
  Abbeville, France Recruiting
• CH du Pays d'Aix
  Aix-en-Provence, France Recruiting
• CHU Amiens - Hôpital Sud
  Amiens, France Recruiting
• CHU Angers
  Angers, France Recruiting
• CHR Metz-Thionville - Hôpital de Mercy
  Ars-Laquenexy, France Recruiting
• CH Henri Duffaut Avignon
  Avignon, France Recruiting

Study contacts

• Principal investigator: Marie-Ange MASSIANI, MD — Institut Curie
• Study coordinator: Marie-Ange MASSIANI, MD
• Email: marieange.massiani@curie.fr
• Phone: +33 1 47 11 15 15

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Concise coaching to guide decisions for advanced cancer patients considering palliative procedures

  A coaching program delivered by lay providers will test whether it helps adults with advanced cancer make better, patient-aligned decisions about palliative surgeries or similar interventions.

  Recruiting Singapore General Hospital · Singapore · NCT07789093

• Primary Palliative Care: A Feasibility Project for Family Health Units

  This feasibility trial tests a GP training program plus a structured 12-week palliative-care visit plan to see if it can be carried out in primary care for adults with advanced illness.

  Recruiting University of Coimbra · Coimbra and 1 other locations · NCT07737899

• Virtual Group Resilient Living for Advanced Cancer

  A group-based online program tests whether seven weekly sessions can reduce anxiety and fatigue and improve quality of life for adults with advanced cancer.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07659158

• IV contrast-enhanced CBCT with HyperSight for image guidance in advanced cancer radiotherapy

  This study tests whether giving IV contrast during cone-beam CT helps doctors see the tumor better during radiotherapy in people with advanced cancer.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07648160

• Single-session celiac plexus SBRT using a simulation-free adaptive workflow for cancer-related pain

  A pilot test to see if a one-day, simulation-free adaptive radiotherapy process can safely deliver celiac plexus SBRT to adults with advanced pancreatic or other cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07636382

• UI-102 in advanced cancers (phase 1/2) first-in-human

  A first-in-human study tests UI-102, given to adults with advanced solid tumors to see if it is safe and shows signs of benefit.

  Recruiting at 3 sites Phase 1/2 United Immunity, co., Ltd. · Dallas, Texas and 2 other locations · NCT07605962

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.